Orchid Pharma presented a mixed financial performance.

Q4FY26 revenue was stable at ₹238 Cr, with EBITDA up 5% to ₹42 Cr and PAT rising 7% to ₹30 Cr.

However, for the full FY26, revenue dropped 12% to ₹811 Cr, EBITDA fell 36% to ₹101 Cr, and PAT decreased significantly to ₹45 Cr from ₹106 Cr in FY25. The company highlights a journey from a ₹96 Cr PAT loss in FY21 to a profit in FY26. Strategic focus includes backward integration into 7-ACA (Key Starting Material) with a ₹750 Cr project commissioning in FY27, aiming for 1,000 MT capacity to reduce import dependence.

Forward integration into Finished Dosage Form (FDF) targets launching 5-6 sterile products in the US by 2030 to capture higher margins.

Recent developments include the ongoing merger to consolidate facilities and unify R&D, creating a stronger platform.

Orchid is also building a 1 million vial capacity for Cefiderocol, a next-generation antibiotic, with a ₹200 Cr investment, focusing on accessible pricing for emerging markets.

Management emphasizes building an integrated anti-infectives model, moving beyond turnaround to platform creation.

The long-term ambition is to establish a differentiated position in critical antibiotics.